The Italian Medicines Agency would like to inform you of the following:

• Cases of thrombocytopenia, including immune thrombocytopenia (ITP), have been reported after receiving Vaxzevria, typically within the first four weeks after vaccination.
• Very rarely, these events of thrombocytopenia presented with very low platelet levels (<20,000 per μL) and/or were associated with bleeding.
• Some of these cases occurred in individuals with a history of immune thrombocytopenia.
• Cases with  fatal outcome have been reported.
• If an individual has a history of a thrombocytopenic disorder, such as immune thrombocytopenia, the risk of developing low platelet levels should be considered before administering the vaccine and platelet monitoring is recommended after vaccination.